Agenus Inc. (NASDAQ: AGEN)
$15.60
-0.0050 ( -0.03% ) 481.0K
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
Market Data
Open
$15.60
Previous close
$15.60
Volume
481.0K
Market cap
$327.59M
Day range
$14.81 - $15.80
52 week range
$4.78 - $36.80
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Oct 23, 2023 |
4 | Insider transactions | 1 | Oct 16, 2023 |
4 | Insider transactions | 1 | Oct 10, 2023 |
4 | Insider transactions | 1 | Oct 06, 2023 |
4 | Insider transactions | 1 | Oct 04, 2023 |
4 | Insider transactions | 1 | Oct 04, 2023 |
4 | Insider transactions | 1 | Oct 04, 2023 |
4 | Insider transactions | 1 | Sep 25, 2023 |
4 | Insider transactions | 1 | Sep 11, 2023 |
4 | Insider transactions | 1 | Aug 31, 2023 |